Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-04-26

Clinical Trial Update: Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents [EARLY_Phase 1]

View source ↗

Summary

Early-phase trial assessing growth hormone to treat nonalcoholic fatty liver disease in adolescents has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Growth Hormone (somatropin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: NAFLD | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2021-04-26